{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:53:37Z","timestamp":1770339217506,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020207","name":"Health Commission of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inhaled corticosteroids (ICS) are a cornerstone of therapy for selected phenotypes of chronic obstructive pulmonary disease (COPD), yet the underlying mechanisms remain incompletely understood. Increasing evidence suggests that airway microbiome and their metabolites play crucial roles in shaping host immune responses and disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study used multi-omics technology to explore the differences in sputum microbiome, metabolites and the systematic connections in patients with stable COPD who use or not ICS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an integrated microbiome\u2013metabolome analysis of induced sputum samples from 53 stable COPD patients (40 ICS users and 13 non-users). Microbial communities were profiled using 16S rRNA sequencing, while metabolic signatures were assessed via liquid chromatography\u2013mass spectrometry. Correlation analyses were conducted to explore microbe\u2013metabolite interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The microbial alpha diversity (Simpson, Shannon, Pielou indices; P &amp;lt; 0.05) was significantly reduced in the ICS group, and the beta diversity was distincted between the two groups. The relative abundance of\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      ,\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      was significantly reduced, and the relative abundance of\n                      <jats:italic>Veillonella<\/jats:italic>\n                      was significantly increased in the ICS group (P &amp;lt; 0.05). Metabolomic profiling identified 70 differential metabolites enriched in pathways including caffeine metabolism, cobalamin transport and metabolism, and cysteine\/methionine metabolism. Notably,\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      abundance was negatively correlated with methylxanthine intermediates (caffeine, theobromine, 1,7-dimethylxanthine, 1-methylxanthine), while Veillonella abundance showed positive correlations with these metabolites (P &amp;lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that ICS therapy not only reshapes the airway microbial ecosystem but also alters host\u2013microbe co-metabolic pathways, particularly caffeine metabolism. By reducing microbial degradation of methylxanthines, ICS may enhance the bioavailability of bronchodilatory compounds, providing a potential microbiome-mediated adjunctive mechanism of action. These insights advance our understanding of ICS pharmacology in COPD and highlight the therapeutic potential of targeting microbiome\u2013metabolite interactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1714879","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:27Z","timestamp":1764656787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Airway microbial and metabolic features associated with ICS therapy in COPD"],"prefix":"10.3389","volume":"16","author":[{"given":"Lijun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14737167.2020.1678385","article-title":"The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature","volume":"20","author":"Anees","year":"2020","journal-title":"Expert Rev. pharmacoecon. Outcomes Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/ph3030514","article-title":"Inhaled corticosteroids","volume":"3","author":"Barnes","year":"2010","journal-title":"Pharm. (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/mi.2017.75","article-title":"Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids","volume":"11","author":"Cait","year":"2018","journal-title":"Mucosal Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1430606","DOI":"10.3389\/fnut.2024.1430606","article-title":"Genetic information supports a causal relationship between trace elements, inflammatory proteins, and COPD: evidence from a Mendelian randomization analysis","volume":"11","author":"Cao","year":"2024","journal-title":"Front. Nutr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/s2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"8","author":"Collaborators","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1700451","DOI":"10.1183\/13993003.00451-2017","article-title":"Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD","volume":"50","author":"Contoli","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.19540\/j.cnki.cjcmm.20211203.501","article-title":"Serum metabolomics of chronic obstructive pulmonary disease with lung-Qi deficiency syndrome","volume":"47","author":"Duan","year":"2022","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/thoraxjnl-2012-201924","article-title":"Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD","volume":"67","author":"Garcha","year":"2012","journal-title":"Thorax"},{"key":"B9","doi-asserted-by":"publisher","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","year":"2025","DOI":"10.11656\/j.issn.1672-1519.2015.12.01"},{"key":"B10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1042\/cs20191202","article-title":"Effects of corticosteroids on COPD lung macrophage phenotype and function","volume":"134","author":"Higham","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaci.2010.10.048","article-title":"Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma","volume":"127","author":"Huang","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"230084","DOI":"10.1183\/16000617.0084-2023","article-title":"How inhaled corticosteroids target inflammation in COPD","volume":"32","author":"Lea","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/resp.12732","article-title":"COPD and the microbiome","volume":"21","author":"Mammen","year":"2016","journal-title":"Respirology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/children8040298","article-title":"Evidence for the management of bronchopulmonary dysplasia in very preterm infants","volume":"8","author":"Muehlbacher","year":"2021","journal-title":"Child. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fnins.2020.00740","article-title":"Vitamin B12 supplementation and NT-proBNP levels in COPD patients: a secondary analysis of a randomized and controlled study in rehabilitation","volume":"14","author":"Paulin","year":"2020","journal-title":"Front. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e47305","DOI":"10.1371\/journal.pone.0047305","article-title":"The lung microbiome in moderate and severe chronic obstructive pulmonary disease","volume":"7","author":"Pragman","year":"2012","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0207675","DOI":"10.1371\/journal.pone.0207675","article-title":"Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate","volume":"14","author":"Provost","year":"2019","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2152656718789519","DOI":"10.1177\/2152656718789519","article-title":"Determinants of the nasal microbiome: pilot study of effects of intranasal medication use","volume":"9","author":"Ramakrishnan","year":"2018","journal-title":"Allergy Rhinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","article-title":"Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/all.13502","article-title":"Intranasal administration of probiotic Lactobacillus rhamnosus GG prevents birch pollen-induced allergic asthma in a murine model","volume":"74","author":"Spacova","year":"2019","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0184566","DOI":"10.1371\/journal.pone.0184566","article-title":"Atopic asthmatic immune phenotypes associated with airway microbiota and airway obstruction","volume":"12","author":"Turturice","year":"2017","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jamp.2019.1576","article-title":"Global burden of chronic respiratory diseases","volume":"33","author":"Viegi","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1183\/13993003.01406-2015","article-title":"Lung microbiome dynamics in COPD exacerbations","volume":"47","author":"Wang","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/s0140-6736(18)30841-9","article-title":"Prevalence and risk factors of chronic obstructive pulmonary disease in China (the china pulmonary health [CPH] study): a national cross-sectional study","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/s41396-020-0727-y","article-title":"Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease","volume":"14","author":"Wang","year":"2020","journal-title":"ISME J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/2213235x04666160613122429","article-title":"PCA as a practical indicator of OPLS-DA model reliability","volume":"4","author":"Worley","year":"2016","journal-title":"Curr. Metabolomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/s0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:30Z","timestamp":1764656790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":29,"alternative-id":["10.3389\/fphar.2025.1714879"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1714879","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1714879"}}